Immatics (IMTX) Shares Outstanding (Diluted Average) (2021 - 2025)
Immatics' (IMTX) quarterly Shares Outstanding (Diluted Average) came in at $1030.1 in Q2 2025, down 100.0% year-on-year from $111.0 million in Q2 2024, and up 588.54% quarter-over-quarter from $149.6 in Q4 2024.
Immatics (IMTX) Shares Outstanding (Diluted Average) (2021 - 2025) Analysis & Trends
Immatics has disclosed Shares Outstanding (Diluted Average) across 5 years of filings, most recently posting $1030.1 for Q2 2025.
- Shares Outstanding (Diluted Average) for Q2 2025 came in at $1030.1, down 100.0% year-over-year; the trailing twelve-month figure through Jun 2025 was $1030.1 (down 100.0% YoY), and the FY2024 annual result was $149.6, down 100.0% from the prior year.
- Shares Outstanding (Diluted Average) came in at $1030.1 for Q2 2025 at Immatics, up from $149.6 in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $111.0 million in Q2 2024 to a low of $10.86 in Q1 2024.
- The 5-year median for Shares Outstanding (Diluted Average) is $1349.8 (2022), against an average of $31.0 million.
- Across the five-year window, Shares Outstanding (Diluted Average) jumped 11542056.9% in 2023 and sank 100.0% in 2024, its largest moves.
- Immatics' Shares Outstanding (Diluted Average) stood at $74.2 million in 2021, then fell by 5.35% to $70.2 million in 2022, then increased by 23.42% to $86.7 million in 2023, then slumped by 100.0% to $149.6 in 2024, then jumped by 588.54% to $1030.1 in 2025.
- The last three Shares Outstanding (Diluted Average) figures came in at $1030.1 (Q2 2025), $149.6 (Q4 2024), and $43.93 (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Immatics | 14.67 Bn | 14.67 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1,030.08 |
| Dec 31, 2024 | 149.60 |
| Sep 30, 2024 | 43.93 |
| Jun 30, 2024 | 111.00 Mn |
| Mar 31, 2024 | 10.86 |
| Dec 31, 2023 | 86.66 Mn |
| Sep 30, 2023 | 90.77 Mn |
| Jun 30, 2023 | 631,576.15 |
| Dec 31, 2022 | 70.22 Mn |
| Sep 30, 2022 | 786.45 |
| Jun 30, 2022 | 1,184.43 |
| Mar 31, 2022 | 1,515.16 |
| Sep 30, 2021 | 74.19 Mn |
| Jun 30, 2021 | 939.33 |